Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis  Funding from French Government as part of the France Health Innovation Plan 2030 operated by Bpifrance  Paris, France, February 1, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for […]